The role of leptin in the development of tumours of female genital organs  by Markowska, Anna et al.
Markowska et al.: The role of leptin  … 
 
Rep. Pract. Oncol. Radiother. 8 (3) 2003 
THE ROLE OF LEPTIN IN THE DEVELOPMENT OF TU-
MOURS OF FEMALE GENITAL ORGANS 
 
Anna Markowska1, Krzysztof Drews1, Katarzyna Malendowicz1, 
Jolanta Szenajch2 
 
1The Department Perinatology, University of Medical Sciences in Poznań, Poland, 2Laboratory 
of Molecular Oncology, Department of Oncology, Military Institute of Medicine, Szaserów 128, 
Warsaw, Poland 
 
Received May 19th, 2003; received in a revised form October 1st, 2003; accepted October 2nd, 2003 
 
SUMMARY 
 
   Leptin concentrations in blood serum are significantly elevated in women suffering from endometrial 
carcinoma or from advanced breast carcinoma. Controversial results on the relations in other cancers 
of genital organs (ovary, uterine cervix, vulva) and in endometriosis require some further studies. 
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INTRODUCTION 
 
   Leptin (OB protein), the product of ob 
gene is produced mainly by adipocytes 
of the white adipose tissue, from which it is 
secreted to the circulation in a free and 
a bound form. Leptin decreases appetite 
and stimulates energy expenditure by inhi-
biting hypothalamic neuropeptide Y (NPY), 
which stimulates appetite [1,2]. 
   Even if leptin is regarded to represent 
an anti-obesity, anorexia-inducing hormo-
ne, its role is much broader: it participates 
in the control of blood pressure and of he-
mopoiesis, in immune functions, angioge-
nesis, oxidation of lipids, glucose metabo-
lism, reproduction and apoptosis in adipo-
cytes [1,3,4,5,6]. 
   Serum leptin levels reflect the amount 
of adipose tissue in the body, age, sex, 
diet composition, levels of other hormones 
(insulin, steroid hormones) as well as le-
vels of other cytokines, including TNFα 
- tumour necrosis factor α, interleukins 
1 and 6 (IL-1 and IL-6)   [7]. 
   Persons characterized by a low weight 
and low body mass index (BMI) demon-
strate low leptin levels whereas in obese 
individuals these levels are higher. In the 
studies of Considine et al. in the group 
of 136 individuals of a normal weight and 
in 139 obese persons, the leptin levels 
were found to be 7.5 ± 9.3 and 31.3 ± 24.1 
ng/mL, respectively. This indicates that 
most obese individuals are insensitive 
to endogenously produced leptin [6]. 
This insensitivity is linked to resistance 
to leptin and it is suspected to result from 
a mutation of the leptin receptor or from an 
elevated serum leptin threshold (around 
25-30ng/mL). Increased levels of leptin 
in the serum do not increase in parallel 
leptin concentrations in the cerebrospinal 
fluid and the brain [7,8,9]. 
   Leptin acts through its receptor, coded 
by db gene, which exhibits 4 isoforms: 
the long OBRL form and three short OBRS  
forms differing from each other in the num-
ber and sequence of amino acids of the 
cytoplasmic portion of the receptor and 
therefore, in the function of the receptor 
[10]. The leptin receptor (OBR), mainly its 
long isoform, is expressed in the hypo-
thalamus. Prevalent expression of short 
isoforms of the receptor has been detec-
ted in peripheral tissues: in the lungs, kid-
neys, liver, pancreas, suprarenal glands, 
ovaries, skeletal muscles and in the hae-
matopoietic stem cells [1]. 
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   Leptin acts by binding to its specific 
receptors, which is followed by the activa-
tion of the JAK-STAT (just another kinase/ 
signal transducers and activators of trans-
cription) system, linked to the activation 
of kinases, their phosphorylating activity 
and to stimulation of various cytokine re-
ceptors, regulation of gene expression and 
the resulting engagement of various sig-
nalling pathways [10,11]. 
   The number of obese individuals the 
world over is on the increase. Statistical 
data indicate that around 80% of obese 
people suffer from at least one and 70% 
of them from two or more co-existing 
diseases. Obesity participates in the etio-
pathogenesis of certain diseases, such as 
diabetes, hypertension, cardiovascular di-
seases and also some malignant tumours 
[7,12]. 
   Some types of tumours were found to be 
related to obesity: 
   Among 1245 patients with acute myeloid 
leukemia (AML) a group of 120 (9.6%) 
patients was distinguished in whom 
the acute promyelocytic leukemia (APL) 
was diagnosed. As compared to AML 
patients, the latter patients were more 
frequently obese (p = 0.0003). Increased 
BMI (> 50, body weight of 316 to 480 lbs) 
was found to predispose to APL [13,14]. 
   Higher risk of colorectal carcinoma was 
noted in obese individuals of low physical 
activity. In in vitro studies leptin proved 
to act as a growth factor for cells of colo-
rectal carcinoma [15]. In some clinical stu-
dies marked obesity was linked to accele-
rated progression of colorectal carcinoma 
[16]. 
   Some studies indicate that leptin incre-
ases the risk of prostate cancer develop-
ment [17,18]. In the studies on 149 men 
in the population of Northern Sweden 
an intermediate but not high leptin levels 
correlated with the development of cancer 
[17]. Other studies indicate, in turn, that 
elevated leptin concentrations are insi-
gnificant in the development of prostate 
cancer or even in benign hypertrophy 
of the gland [19]. 
   The expression of leptin and that of its 
receptor varies in tumours of different 
histological origin or even in tumours 
of the same origin. In some cases of the 
ovarian, renal or testicular carcinomas 
the expressions of both the leptin and its 
receptor were likely to point to autocrine 
action of leptin, and in other tumours 
(leukemias) the expression of the leptin 
receptor without expression of leptin was 
found, suggesting a systemic or paracrine 
effect of the cytokine on tumour cells [20]. 
In some studies, leptin was linked to the 
anorexia – cachexia syndrome in some 
cancer patients [21,22] but, according 
to Simons et al. [23], leptin does not 
participate in the development of cachexia 
due to lung cancer [21,22]. 
 
BREAST CANCER 
 
   Obese women were found to carry a hig-
her risk of developing breast cancer [24]. 
In the studies of Tessitore et al. [25] on 23 
women with breast cancer plasma leptin 
and insulin levels were higher than in con-
trols. The elevated leptin levels correlated 
with augmented levels of estrogen and 
progesteron receptors and elevated levels 
of breast cancer markers,  CA 15.3, CEA. 
The authors suggest that leptin should be 
treated as a clinical marker of the disease.  
   In the studies of Ozet et al. [26] leptin 
was estimated in 58 women with breast 
cancer and in 58 healthy women, serving 
as a control group. Serum leptin levels 
were significantly higher in the breast can-
cer patients than in the control group 
(27.00 and 17.65 ng/mL, respectively). 
The analysis included also BMI, the age 
of women, the stage of the disease, 
the concentration of CA 15.3 and the hor-
monal status (pre- or post-menopausal). 
Some patients received tamoxifen, some 
did not. 
   No correlation could be detected be-
tween leptin concentration and the early 
or late stages of the cancer, or between 
leptin concentration and CA 15.3 levels. 
Pre-menopausal and post-menopausal 
women did not differ in BMI or leptin 
levels. 
   Women with breast cancer who received 
tamoxifen manifested a significantly higher 
leptin levels than those who received 
no tamoxifen (32.71 and 19.39 ng/mL, 
respectively). Thus, high leptin levels 
in breast cancer patients showed no 
relation to the stage of the disease but 
were related to tamoxifen administration, 
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although the mechanism of the relation 
remained unclear. 
   In other clinical observations [24], 
83 pre-menopausal women with in situ 
carcinoma demonstrated lower leptin le-
vels than 69 healthy women of the control 
group (13.69 ± 1.3 ng/mL and 16.03 
± 1.7 ng/mL, respectively). According 
to the authors, leptin does increase the 
risk of breast cancer development.  
   In in vitro cultures [27] of breast cancer 
cells, expression of leptin mRNA was 
more pronounced than in the adipose 
tissue. This pertained to three cell lines 
(MCF-7, T470 and MDAMB).  
   It has been suggested that leptin may 
play a role in the development of immuno-
suppression in females with breast cancer.  
 
ENDOMETRIAL CARCINOMA 
 
   Its development is related to obesity, 
early menarche, late menopause and 
to high levels of unbalanced estrogens 
[28]. 
   Controlled clinical investigations of Petri-
dou et al. [29] were performed on 84 wo-
men with endometrial carcinoma and on 
84 healthy women of the control group 
with respective BMI values of 29.2 ± 5.72 
and 26.5 ± 3.43. Serum leptin levels in wo-
men with endometrial carcinoma were 
found to be 36.7 ± 25.7 ng/mL and those 
in the control group were 26.9 ± 19.8 ng/mL. 
The difference was significant at p = 0.006. 
   Leptin levels were found to be strongly 
related to endometrial cancer.  
 
UTERINE CERVIX CARCINOMA 
 
   Leptin was detected to induce angio-
genesis [30]. Obermair et al. [31] are 
of the opinion that, apart from the effects 
of the vascular endothelial growth factor 
(VEGF), the angiogenesis factor, neo-
plasia in the form of uterine cervix car-
cinoma is being modulated also by leptin. 
Lebrecht et al. [32] by measuring the le-
vels of leptin and of  VEGF have examined 
the role of the two factors in the develop-
ment of uterine cervix carcinoma in 84 wo-
men with cervical cancer, 28 patients with 
CIN I – III  and in 35 healthy women.  
   Serum VEGF levels were significantly 
elevated (p<0.001) in patients with cervical 
carcinoma and in patients with CIN I-III as 
compared to healthy women. Serum 
VEGF was significantly elevated (p=0.02) 
in women with cervical carcinoma as com-
pared to women with CIN. Serum VEGF 
showed a significant correlation with 
the stage of the tumour but showed no 
such relation to lymph node involvement, 
survival time or the period in which the pa-
tients were free of the disease.  
   Leptin concentrations did not differ in pa-
tients with uterine cervix carcinoma 
(10.9; range: 1.0 to 49.9 ng/mL), those with 
CIN I-III (8.6; range: 1.9 to 42.3 ng/mL) and 
healthy women (10.1; range: 2.4 to 53 ng/ 
mL). They did not correlate with the sur-
vival time or the time in which the patient 
was free of the disease. No correlation 
was demonstrated between concentra-
tions of VEGF and leptin in patients with 
uterine cervix carcinoma, patients with CIN 
I-III and healthy women. 
 
VULVAR CARCINOMA 
 
   Angiogenesis was demonstrated to play 
a significant role in the progression of vul-
var intraepithelial carcinoma to the inva-
sive cancer [33] whereas overexpression 
of VEGF was detected in patients with 
vulvar carcinoma (34). Since angiogenesis 
and adipogenesis are linked to each other, 
it has been advanced that leptin plays 
a role in the development of new vessels 
(leptin-dependent angiogenesis) [4].  
   At the University of Vienna department 
37 patients with vulvar carcinoma and 
37 healthy women were examined. Serum 
leptin levels were higher in the patients 
(15.8; range: 1.1 to 45.6 ng/mL) than in 
healthy women (10.1; range: 2.4 to 53.5 
ng/mL). The authors did not consider 
leptin to be an angiogenic factor since its 
levels did not reflect clinical advancement, 
histological diagnosis or lymph node invol-
vement. Leptin levels also failed to corre-
late with less favourable prognosis [35]. 
 
OVARIAN CANCER 
 
Pilot studies of Szenajch et al. [20] on cell 
lines of the ovarian cancer (OVCAR3, 
OVP10) did not detect leptin, its receptors 
being noted only in the former cell line.  
In tissues of the ovarian cancer, the expre- 
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ssion of the receptor was detected and 
in some of them, the expression of leptin 
was noted. In tissues of benign tumours 
of the ovary, neither leptin nor its receptor 
expression was detected. The authors 
suggest a link between the expression 
of leptin receptor and malignancy. 
   However, in the studies of Karlsson et al. 
[36] the expression of the receptor (more 
pronounced in the short forms) and the ex-
pression of leptin were observed in the ve-
sicular liquid. Clarification of this pheno-
menon requires some further studies.  
 
MEIGS’ SYNDROME 
 
   Leptin levels showed a reverse correla-
tion with Meigs’ syndrome. Following sur-
gery, in the absence of a tumour, with re-
ceding ascites and pleural fluid, when CA 
125 concentrations (from 354 to 14.2) de-
crease, leptin levels increase. The au-
thors have suggested a role of leptin in the 
pathogenesis of Meigs’ syndrome [37].  
 
ENDOMETRIOSIS 
 
   This disease is thought to be associated 
with elevated production of pro-inflamma-
tory cytokines, such as interleukins (IL-1 
and IL-8), TNF α and VEGF. Moreover, 
in the development of endometrial im-
plants, significant role is played by infla-
mmatory mediators and neoangiogenesis. 
Theoretically, a certain role could be as-
cribed also to leptin: inflammatory cyto-
kines such as IL-1 and TNFα stimulate 
leptin secretion while leptin, in turn, indu-
ces some increase in the levels of certain 
cytokines and plays the role of angioge-
nesis-promoting factor [5, 30, 38]. 
   In their multicentre studies only two 
years ago, Matarese et al. [39] noted 
some higher serum and ascitic fluid levels 
of leptin (30.3 ± 14.8 ng/mL and 35.9 
± 17.4 ng/mL, respectively) in 13 women 
with various clinical stages of endome-
triosis as compared to 15 women of the 
control group. The authors suggest that 
pro-inflammatory and neoangiogenetic 
effects of leptin may play a role in the pa-
thogenesis of endometriosis.  
   In 2002, results of some studies, inclu-
ding multicentre studies on leptin in endo-
metriosis have turned out to be completely 
different from those discussed above [40]. 
These studies were carried out on 42 wo-
men with various clinical stages of endo-
metriosis and on 25 women of the control 
group. Serum leptin levels were similar 
in the two groups of women (2.1 ± 8 ng/mL 
and 12.5 ± 9.4 ng/mL, respectively). 
No differences were revealed in leptin con-
centrations in the analysis of the disease 
stages, number of implants, cysts, depth 
of endometriosis or its signs/symptoms. 
   Some further studies seem to be requi-
red for the clarification of the problems. 
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